Patrick Gonzalez, PhD

Title: Senior Director of Clinical Science Solid Biosciences

Bio: Patrick Gonzalez, Ph.D., currently serves as Senior Director of Clinical Science at Solid Biosciences. Dr. Gonzalez is a muscle biologist by training, having primarily focused on characterizing the molecular biology and physiology associated with skeletal and cardiac muscle pathology in Duchenne muscular dystrophy. Since joining Solid in 2016 he has led non-clinical pharmacology, translational, and clinical bioanalytical and functional analysis efforts, collaborating closely with academic research, clinical, and industry partners. He holds a Ph.D. in Cell Biology and Molecular Medicine from Rutgers University and a B.S. in Biochemistry from Syracuse University.

2023 FUTURES: Gene Therapy and Gene Editing Sessions

A brief primer on the gene therapy and gene editing approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Jahannaz Dastgir, DO

Clinical Development Lead REGENXBIO

Patrick Gonzalez, PhD

Senior Director of Clinical Science Solid Biosciences

Teji Singh, MD

Vice President, Head of Clinical Development Sarepta Therapeutics

Dan Levy, MD

VP and Development Head, Rare Neurology Pfizer

2024 FUTURES GENE Therapy panel

Gene Therapy Approaches to Treatment We covered the rationale behind gene therapy approaches for Duchenne and received updates from Pfizer, Sarepta Therapeutics, REGENXBIO Inc., and Solid BioSciences.

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

Jahannaz Dastgir, DO

Clinical Development Lead REGENXBIO

Patrick Gonzalez, PhD

Senior Director of Clinical Science Solid Biosciences

Robyn van Poelgeest, MD, PhD

Sarepta